GTS5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| Line 50: | Line 50: | ||
|[[GTS5:Multiple_endocrine_neoplasia_type_2_(RET)|Multiple endocrine neoplasia type 2 (RET)]] | |[[GTS5:Multiple_endocrine_neoplasia_type_2_(RET)|Multiple endocrine neoplasia type 2 (RET)]] | ||
|Disease | |Disease | ||
|Amrit Kaler, MD | |||
|7/15/2024 | |||
| | | | ||
|PENDING | |||
| | | | ||
| | |Eric McGinnis | ||
| | | | ||
| | | | ||
| Line 270: | Line 270: | ||
|[[GTS5:Multiple_endocrine_neoplasia_type_1_(MEN1)|Multiple endocrine neoplasia type 1 (MEN1)]] | |[[GTS5:Multiple_endocrine_neoplasia_type_1_(MEN1)|Multiple endocrine neoplasia type 1 (MEN1)]] | ||
|Disease | |Disease | ||
|Amrit Kaler, MD | |||
|7/15/2024 | |||
| | | | ||
|PENDING | |||
| | | | ||
| | |Eric McGinnis | ||
| | | | ||
| | | | ||
| Line 281: | Line 281: | ||
|[[GTS5:Peutz-Jeghers_syndrome_(STK11)|Peutz-Jeghers syndrome (STK11)]] | |[[GTS5:Peutz-Jeghers_syndrome_(STK11)|Peutz-Jeghers syndrome (STK11)]] | ||
|Disease | |Disease | ||
|Amrit Kaler, MD | |||
|7/15/2024 | |||
| | | | ||
|PENDING | |||
| | | | ||
| | |Eric McGinnis | ||
| | | | ||
|Named based on GTS5 book (page created 7/12/24). Also, content in online WHO MALE5, FEMA5, BRST5, DIG5, | |Named based on GTS5 book (page created 7/12/24). Also, content in online WHO MALE5, FEMA5, BRST5, DIG5, | ||
| Line 380: | Line 380: | ||
|[[GTS5:PTEN_hamartoma_tumour_syndrome_(PTEN)|PTEN hamartoma tumour syndrome (PTEN)]] | |[[GTS5:PTEN_hamartoma_tumour_syndrome_(PTEN)|PTEN hamartoma tumour syndrome (PTEN)]] | ||
|Disease | |Disease | ||
|Amrit Kaler, MD | |||
|7/15/2024 | |||
| | | | ||
|PENDING | |||
| | | | ||
| | |Eric McGinnis | ||
| | | | ||
| | | | ||
| Line 488: | Line 488: | ||
|[[GTS5:SDH-deficient_tumour_syndrome_-_Hereditary_phaeochromocytoma-paraganglioma_syndromes_(SDHA,_SDHB,_SDHC,_SDHD,_SDHAF2)|SDH-deficient tumour syndrome - Hereditary phaeochromocytoma-paraganglioma syndromes (SDHA, SDHB, SDHC, SDHD, SDHAF2)]] | |[[GTS5:SDH-deficient_tumour_syndrome_-_Hereditary_phaeochromocytoma-paraganglioma_syndromes_(SDHA,_SDHB,_SDHC,_SDHD,_SDHAF2)|SDH-deficient tumour syndrome - Hereditary phaeochromocytoma-paraganglioma syndromes (SDHA, SDHB, SDHC, SDHD, SDHAF2)]] | ||
|Disease | |Disease | ||
|Amrit Kaler, MD | |||
|7/15/2024 | |||
| | | | ||
|PENDING | |||
| | | | ||
| | |Eric McGinnis | ||
| | | | ||
| | | | ||
| Line 627: | Line 627: | ||
|[[GTS5:Lynch_Syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Lynch Syndrome (MLH1, PMS2, MSH2, MSH6)]] | |[[GTS5:Lynch_Syndrome_(MLH1,_PMS2,_MSH2,_MSH6)|Lynch Syndrome (MLH1, PMS2, MSH2, MSH6)]] | ||
|Disease | |Disease | ||
|Amrit Kaler, MD | |||
|7/15/2024 | |||
| | | | ||
|PENDING | |||
| | | | ||
| | |Eric McGinnis | ||
| | | | ||
| | | | ||